Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

The immune system can act as an extrinsic suppressor of tumors. Therefore, tumor progression depends in part on mechanisms that downmodulate intrinsic immune surveillance. Identifying these inhibitory pathways may provide promising targets to enhance antitumor immunity. Here, we show that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis. We observed a markedly enhanced function of dendritic cells, T cells, natural killer (NK) cells and neutrophils in tumor-bearing mice with Stat3−/− hematopoietic cells, and showed that tumor regression requires immune cells. Targeting Stat3 with a small-molecule drug induces T cell– and NK cell–dependent growth inhibition of established tumors otherwise resistant to direct killing by the inhibitor. Our findings show that Stat3 signaling restrains natural tumor immune surveillance and that inhibiting hematopoietic Stat3 in tumor-bearing hosts elicits multicomponent therapeutic antitumor immunity.

[1]  P. Musiani,et al.  Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. , 2004, Cytokine.

[2]  J. Blattman,et al.  Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer Cell.

[3]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[4]  Valeria Poli,et al.  Mutational switch of an IL-6 response to an interferon-gamma-like response. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Antonio Lanzavecchia,et al.  Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.

[6]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[7]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[8]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[9]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[10]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[11]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[12]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[13]  Jin Hong Liu,et al.  Control of Lytic Function by Mitogen-activated Protein Kinase/Extracellular Regulatory Kinase 2 (ERK2) in a Human Natural Killer Cell Line: Identification of Perforin and Granzyme B Mobilization by Functional ERK2 , 1998, The Journal of experimental medicine.

[14]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  M. Mizumoto,et al.  Spleen‐derived dendritic cells engineered to enhance interleukin‐12 production elicit therapeutic antitumor immune responses , 2000, International journal of cancer.

[16]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[17]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[18]  M. Smyth,et al.  Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.

[19]  D. Levy,et al.  Cooperation between STAT3 and c-jun suppresses Fas transcription. , 2001, Molecular cell.

[20]  J. Turkson,et al.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. , 2004, Molecular cancer therapeutics.

[21]  Youjin Lee,et al.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.

[22]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[23]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[24]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[25]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[26]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[27]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[29]  A. Cuenca,et al.  Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. , 2001, Blood.

[30]  H. Maguire,et al.  Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. , 1999, Cancer research.

[31]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[32]  Christophe Caux,et al.  Tumour escape from immune surveillance through dendritic cell inactivation. , 2002, Seminars in cancer biology.

[33]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[34]  R. Flavell,et al.  STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.

[35]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Trinchieri,et al.  Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.

[37]  Valeria Poli,et al.  Mutational switch of an IL-6 response to an interferon-γ-like response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[39]  C. Desponts,et al.  Influence of SHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation , 2002, Science.

[40]  N. Shastri,et al.  Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages , 2000, Nature Immunology.

[41]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[42]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[43]  M. Colombo,et al.  Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.

[44]  M. Baccarani,et al.  Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.

[45]  M Aguet,et al.  Inducible gene targeting in mice , 1995, Science.

[46]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.